<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc.

    Hoth Therapeutics is a development stage biopharmaceutical company focused on prop...

    Hoth Therapeutics is a development stage biopha...

    Filing Type:    PU
    InVivo Therapeutics Holdings Corp.

    InVivo Therapeutics Holdings Corp.

    Armed with cutting-edge technology and MIT science, experienced business and medic...

    Armed with cutting-edge technology and MIT scie...

    Filing Type:    PU
    Kodiak Sciences Inc

    Kodiak Sciences Inc

    Kodiak Sciences is a clinical stage company developing innovative therapeutics to ...

    Kodiak Sciences is a clinical stage company dev...

    Filing Type:    PU
    Delee Corp

    Delee Corp

    At Delee, we aim to radically change the way cancer is detected, monitored and tre...

    At Delee, we aim to radically change the way ca...

    Fundraising Status:    EC
    Filing Type:    CF
    IntriCon Corporation

    IntriCon Corporation

    For more than 40 years, IntriCon has been meeting the rising demand for smaller, p...

    For more than 40 years, IntriCon has been meeti...

    Filing Type:    PU
    NeoGenomics, Inc.

    NeoGenomics, Inc.

    NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and phar...

    NeoGenomics, Inc. is a high-complexity CLIA-cer...

    Filing Type:    PU
    Merck KGaA

    Merck KGaA

    Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...

    Merck KGaA, Darmstadt, Germany, a leading scien...

    Filing Type:    PU
    NextCure, Inc.

    NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering an...

    NextCure is a clinical-stage biopharmaceutical ...

    Filing Type:    PU
    Vaccinex, Inc.

    Vaccinex, Inc.

    Vaccinex is a clinical-stage biotechnology company engaged in the discovery and de...

    Vaccinex is a clinical-stage biotechnology comp...

    Filing Type:    PU
    Sesen Bio, Inc.

    Sesen Bio, Inc.

    At Sesen Bio, we are committed to renewing life for people with cancer. We are a l...

    At Sesen Bio, we are committed to renewing life...

    Filing Type:    PU
    Replimune Group, Inc.

    Replimune Group, Inc.

    Cancer is one of the most difficult diseases to treat. It is constantly changing, ...

    Cancer is one of the most difficult diseases to...

    Filing Type:    PU
    G1 Therapeutics, Inc.

    G1 Therapeutics, Inc.

    G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on th...

    G1 Therapeutics, Inc., is a clinical-stage biop...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.